-
-
-
-
-
-
-
Immix Biopharma, Inc. (IMMX) PT Raised to $20 at H.C. Wainwright
-
-
-
-
-
-
-
Immix Biopharma, Inc. (IMMX) PT Raised to $15 at Mizuho
-
-
-
-
-
-
-
Immix Biopharma surpasses 50% enrollment in AL amyloidosis trial
-
-
-
-
-
-
-
Immix Biopharma (IMMX) Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
-
-
-
-
-
-
-
Immix Biopharma (IMMX) Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
-
-
-
-
-
-
-
RenovoRx (RNXT) Appoints Ryan Witt as SVP of Head of Corporate Strategy and Partnerships
461,087 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

